Articles, Advanced therapy medicinal products
29 results
Applied filters
Introduction to advanced therapy medicinal products (ATMPs)
25 February 2026ATMPs are biological medicines that use cells, genes or tissues to treat complex conditions including cancers, rare diseases and genetic disorders.
Ex-vivo GMO gene therapy medicinal products
13 February 2026This document outlines key areas for focus of pharmacy expertise prior to an organisation implementing ex-vivo genetically modified organism (GMO) gene therapy.
In-vivo GMO gene therapy medicinal products
13 February 2026This document outlines key areas for focus of pharmacy expertise prior to an organisation implementing in-vivo genetically modified organism (GMO) gene therapy.
Tissue engineered products
13 February 2026This document outlines key areas for focus of pharmaceutical expertise prior to an organisation implementing tissue engineered products.
Exagamglogene autotemcel (Casgevy®)
13 February 2026This document highlights key areas where Chief Pharmacists should focus pharmaceutical expertise prior to implementation of exagamglogene autotemcel.
Ex-vivo non-GMO gene therapy medicinal products
13 February 2026This document outlines key areas for focus of pharmacy expertise prior to an organisation implementing ex-vivo non-genetically modified organism gene therapies.
Marketed CAR-T therapy
13 February 2026This document outlines key areas where Chief Pharmacists should focus pharmaceutical expertise prior to an organisation implementing CAR-T therapy.
In-vivo non-GMO gene therapy medicinal products
13 February 2026This document outlines key areas for focus of pharmacy expertise prior to an organisation implementing in-vivo non-genetically modified organism gene therapies.
Somatic cell therapy medicinal products
13 February 2026This document outlines key areas for focus of pharmaceutical expertise prior to an organisation implementing somatic cell therapy product.
Operating as an NHS clinical trial site post EU Exit
11 February 2026A summary of the implications of the UKs exit from the EU for clinical trial sites for both IMP and ATIMPs, including supply to and from Northern Ireland.